Scipio bioscience is a French biotech startup developing, manufacturing and selling laboratory kits and analysis software for single-cell RNA sequencing (scRNA-seq). Single-cell sequencing is a most promising technology which greatly enhances possibilities of existing bulk genomic sequencing. Our goal is to enable all life-science researchers to easily access this new single-cell technology by breaking down the technical, logistical, and financial barriers through scientific innovation.
Scipio bioscience is backed by leading VCs (Seventure, M Ventures, HTGF, Verve Ventures, Arbevel) after 2 financing rounds: 1.5m€ seed in September 2017 and 6m€ Series A in January 2020. We are based in Paris 14 (at the hospital Cochin within the Paris Biotech Santé incubator) and our business language is English.
Our first commercial solution, based on the innovative proprietary method RevGel-seq, has been announced at the Festival of Genomics & Biodata last January (watch our CEO’s presentation here) and released in May 2022. It consists of the Asteria benchtop kit for scRNA-seq sample preparation and its companion software Cytonaut for cloud-based data analysis.
If you interested in knowing more about us or our products, please feel free to contact us and we’ll get back to you shortly!